ArticleERJ open research2025
Long COVID-19 and longer sick leave: longitudinal study of economically active patients.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sick leave was one of the numerous consequences of the COVID-19 pandemic. Given the relevance of occupational status for any individual, the aim of the study was to evaluate the impact of persistent symptoms after active infection and determine factors associated with longer sick leaves (LSLs). Methods: This observational study focused on economically active patients attending a post-COVID outpatient clinic for persistence of symptoms or radiological alterations after active infection. The LSL temporal cut-off point was defined by the third tertile of total leave days. Median leave time was compared with the optimal sick leave time for any other viral pneumonia, estimated by the local Ministry of Employment. To determine factors associated with LSL, multivariate models were ultilised. Results: A total of 248 patients were included. The median sick leave time for the entire population was 53 days (interquartile range (IQR) 37.0-126.5), global sum of 30 169 days; the median optimal sick leave time was 21.9 days (IQR 19.7-25.9) (p<0.05). The third tertile cut-off point for LSL was 83 days and multivariate analysis showed a significant association with dyspnoea (OR 3.26, 95% CI 1.59-6.70, p=0.0001), while physical exercise of at least 10 min·day Discussion: COVID-19 sick leave was considerably longer than that stipulated for nonsevere acute respiratory syndrome coronavirus 2 viral pneumonia. Long-COVID syndrome, especially dyspnoea, seems to be a very present factor in these patients' inability to work.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.